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ABSTRACT
Stinging insect allergy is a relatively common medical
problem, responsible for an estimated 40 fatalities
per year in the USA and considerable anxiety and
lifestyle modification. There are no criteria to identify
people at risk of initial venom anaphylaxis. Reactions
may occur at any age and are unrelated to the time
interval of prior venom exposure. There is an approxi-
mate 60% re-sting reaction rate in people who have
had sting anaphylaxis and have positive venom skin
tests. Re-sting reactions are more likely to occur in
adults than in children and in people who have had
more severe anaphylactic symptoms. Positive venom
intradermal skin tests confirm the diagnosis of poten-
tial stinging insect allergy in people who have
had sting reactions. Venom immunotherapy provides
almost 100% protection from further sting reactions.
It is recommended for all people who have had
venom anaphylaxis and have positive skin tests,
except for children who have dermal reactions only.
Details of venom dosing are well established. The
adequate duration of venom immunotherapy is still
an unresolved issue. Conversion to a negative skin
test appears to be an absolute criterion to discontinue
treatment. In the presence of a persistent positive
skin test, 3–5 years of immunotherapy is generally
sufficient. People who have had severe reactions,
such as loss of consciousenss, may require indefinite
therapy.
Key words: clinical reactions, diagnosis, immuno-
therapy, natural history, venom allergy.
INTRODUCTION
Over the past 20 years, the pathogenesis, diagnosis and
treatment of allergic reactions due to insect stings have
been clarified and reliable guidelines established for the
assessment of this allergic disease. The availability of puri-
fied insect venoms and the clinical application of measure-
ments of venom specific IgE (skin test, radioallergosorbent
test (RAST)) and serum venom specific IgG provided the
appropriate tools to understand and modulate this disease
process. Criteria have been established for the use of
venom as a diagnostic skin test reagent, correlating with
the clinical presence of potential insect sting allergy. Insect
venom immunotherapy (VIT) is a remarkably effective ther-
apy for individuals at potential risk of insect sting anaphy-
laxis, inducing a permanent ‘cure’ in many individuals.
There are still pertinent unresolved issues. These include
the identification of individuals who may be at risk for
initial insect sting anaphylaxis, further insight into the
factors which affect the natural history of venom allergy,
and objective criteria to define the adequate length of
immunotherapy.
DEVELOPMENT OF INSECT STING ALLERGY
At present there are no predictive criteria that identify
individuals at risk of acquiring an insect sting allergy. The
majority of individuals who have insect sting anaphylaxis
have tolerated prior stings without reaction. In our experi-
ence, there is no time relationship between the last
uneventful sting and the subsequent sting which leads to
an allergic reaction. A further confusing observation is
the fact that some individuals, primarily children, have
had venom anaphylaxis after the first known insect sting.
As insect stings always cause pain, in contrast to insect
bites, the history in this regard seems reliable. This occur-
ence raises the issue regarding the cause of sensitization
or the pathogenesis of this initial reaction.
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In the past, there was a common accepted concept
that large local reactions following insect stings, particu-
larly those that were increasing in size with each sting,
might precede an anaphylactic reaction. These large
local reactions are defined as reactions extending from
the sting site, often peaking in 24–48 h and lasting up to
one week. For example, a sting on the finger may extend
to the wrist or elbow. Clinical observations in recent years
indicate that these large local reactions tend to be repeti-
tive, with a very low incidence, perhaps less than 5%, of
subsequent systemic allergic reactions.1
Venoms are highly potent sensitizing substances when
there is significant exposure. Observations in the past,
such as individuals who collect snake venoms, indicate a
high incidence of the development of an inhalant type
allergy to venom. The occurence of many simultaneous
stings such as 100–200 stings, can sensitize individuals
for subsequent single sting anaphylaxis. This potential
problem is now recognized more often because of the
increasing spread of the so called ‘killer bees’, which may
inflict several hundred stings at one time.2
Demographic studies suggest that the incidence of insect
sting allergy in the general population ranges between
0.4 and 3%.3–5 Approximately 33–40% of individuals who
have insect sting anaphylaxis are atopic. There is a 2:1
male to female ratio which is probably a reflection of expo-
sure rather than any specific sex prevalence. The majority
of the reactions which do occur are in younger individuals
although fatalities are greater in adults.
Severe anaphylactic symptoms following insect stings
may occur at any age. In one large study, potentially
fatal anaphylaxis as defined by hypotension, loss of
consciousness, upper airway swelling, and marked respi-
ratory distress occured in individuals who had a fairly
uniform age distribution, including children.6 The major-
ity of the individuals who had severe reactions were not
aware of their potential allergic sensitivity.
It is estimated that there are 40–50 deaths per year in
the United States as a result of insect sting anaphylaxis.7
Most individuals had no warning or indication of their
sensitivity and had tolerated prior stings with no difficulty.
NATURAL HISTORY OF INSECT
STING ANAPHYLAXIS
In order to assess appropriate intervention, it is necessary
to understand the natural history of any disease process.
This is particularly true of insect sting allergy. Extracts pre-
pared by crushing or grinding old insect bodies, so called
whole-body insect extracts, were used for over 40 years
for diagnosis and treatment. It was generally accepted
that these extracts were therapeutically potent and pro-
vided protection against further sting reactions. It is now
clear that these whole-body extracts are impotent, lack
sufficient venom content, are unreliable for diagnosis and
ineffective for treatment. The only explanation for this
mistaken confidence was the failure to understand the
natural history of insect sting allergy. Individuals may
spontaneously lose their allergic sensitivity.
More recent observations of individuals who have had
allergic reactions from insect stings and who do not receive
VIT have provided insights into the natural history of insect
sting allergy and suggest that this allergy is a self-limiting
process for many individuals. In the initial study which docu-
mented the efficacy of venom therapy, 40% of individuals
treated with placebo or whole body extracts failed to react
to subsequent re-stings.8 In a subpopulation of children
who have had dermal (hives, angiedema) symptoms as the
only manifestation of an allergic reaction from an insect
sting, there is an extraordinarily low re-sting reaction rate.9
These observations were extended in a study of a large
number of individuals who had insect sting reactions and
were observed without treatment.10 Overall, the incidence
of re-sting reactions was higher in adults than in children,
but did average about 60%. There was no relationship
between the time interval between the sting reaction and
the subsequent re-sting. The severity of the anaphylactic
symptoms was an important criterion. Those individuals
with more severe reactions had a higher incidence of
re-sting reactions. Finally, when a re-sting reaction did
occur, the symptoms generally were similar to those which
had occured previously. These observations confirmed the
frequent self-limiting course of insect sting allergy, espe-
cially in children, and the repetitive nature of the specific
anaphylactic symptoms.
CLINICAL REACTIONS
The clinical symptoms of insect sting anaphylaxis are
similar to those occuring from other causes of anaphylaxis.
Cutaneous reactions, urticaria and angiedema, occur in a
large majority of individuals. Other symptoms include
upper airway obstruction, asthma, circulatory collapse with
shock and hypotension, nausea, diarrhea, bowel contrac-
tions, cardiac arrhythmias and, on rare occasions, uterine
contractions. Milder symptoms such as the dermal reac-
tions are self-limited and usually resolve within several
hours in the absence of any medical therapy.
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As noted above, severe symptoms may occur at any
age.6 In the group of people who had loss of conscious-
ness, individuals were older and had a higher incidence
of cardiac disease and beta blocker use. The majority
of these individuals had no warning or indication of
potential anaphylaxis.
Anaphylactic symptoms usually occur within minutes
after the insect sting. In general, the shorter the time inter-
val between the insect sting and the onset of symptoms,
the greater the severity of the reaction. On occasion,
however, reactions, primarily urticaria, may start 6–24 h
after the sting. On rare occasions these delayed onset
reactions are also associated with more acute symptoms
such as throat edema and shortness of breath.
Serum sickness such as reactions characterized by
hives and arthralgia and fever may occur seven to
14 days after an insect sting.11 These late onset reactions
are mediated by IgE antibodies. These individuals are
candidates for VIT.
DIAGNOSIS-DETECTION OF VENOM SPECIFIC IgE
Venom skin tests
The diagnosis of potential venom allergy is dependent
upon the history of insect sting anaphylaxis and the pres-
ence of venom specific IgE, usually detected by the
immediate skin test reaction. Both of these components
are necessary to substantiate the diagnosis of insect sting
allergy and the possibility of administering VIT.
A positive venom skin test without a history of an
allergic reaction does not indicate that there is a risk for
venom anaphylaxis. The majority of individuals who
have had large local insect sting reactions do have
positive venom skin tests, but as noted above, have a
small risk of anaphylaxis. Some individuals who tolerate
insect stings with no problem will have a transient posi-
tive skin test.
In the United States there are five commercial venoms.
These are honeybee, yellow jacket, Polistes wasp, yellow
hornet and white faced hornet. The yellow jacket and
Polistes are mixed species preparations. Individuals sus-
pected of having insect sting allergy are usually tested with
all five venoms. Intradermal tests are performed, starting
with venom doses usually in the range of 0.0001 m g/mL
and testing up to concentrations of 0.1–1.0 m g/mL.12,13
Greater venom concentrations may cause irritative reac-
tions, which are not immunologically specific. Skin test
reactions which occur only at the 1 m g/mL dose must be
carefully evaluated for clinical relevance. In our own expe-
rience there have been no systemic reactions from venom
testing and only rare local reactions.
In vitro measurement of venom specific IgE
Venom specific IgE can also be measured in the serum by
in vitro tests (RAST). In general, the skin test is a more
sensitive test for detection of venom specific IgE than
the in vitro test. In addition, the sensitivity of the in vitro
test may vary considerably from laboratory to laboratory.
The skin test remains the preferred test for diagnosis of
venom allergy. When skin tests cannot be performed or
cannot be reliably interpreted, such as in individuals with
dermatographia, or when they give equivocal results in
the presence of a highly suspect history, measurement of
serum venom specific IgE may be helpful.
IMMUNITY
An important aspect related to the understanding and
treatment of venom allergy is the development of immu-
nity. Initial studies of immunity were carried out with
beekeepers who represent an immune population, the
antithesis to the allergic individual. Beekeepers may be
stung on multiple occasions with little local reaction. They
have even expressed the thought that ‘I would rather
be stung by a bee than bitten by a mosquito’. Investigation
of beekeepers has shown the presence of high titers of
venom specific IgG, often correlating with the amount
of venom exposure (stings).14
More specific documentation of the role of venom
specific IgG came from studies which showed that
passive administration of hyperimmune gamma globulin
obtained from beekeepers protected honeybee allergic
individuals from allergic reactions due to venom chal-
lenge.15 Finally, the protective effects of VIT, at least
during early treatment, appear to be related to the stimu-
lation of venom specific IgG.
TREATMENT
Acute reaction
The medical treatment for acute anaphylaxis is the same
as that for anaphylaxis due to any cause. Epinephrine is
the drug of choice and should be administered as soon
as possible, even if symptoms are mild. The use of other
medications depends upon the symptom complex and
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includes antihistamines, steroids, oxygen and vasopres-
sors. Specific attention should be directed at the upper
airway, as upper airway swelling has been a major cause
of death. Airway patency must be maintained.
If the insect stinger remains in the skin, which most fre-
quently occurs after honeybee stings, it should be gently
flicked off. Care should be taken to avoid squeezing
the sac which could deposit more venom. Because the
majority of venom is deposited very quickly after the sting,
this procedure may not be very helpful unless done
immediately after the sting.16
Prophylaxis
Individuals at risk of an allergic reaction are advised to use
precautions to avoid subsequent stings. When outside,
especially when involved with activities which might
increase insect exposure such as gardening, these individ-
uals should wear slacks, long-sleeved shirts and shoes.
Cosmetics, perfumes and hair sprays which attract insects
should be avoided. Dark or drab clothing is less likely to
attract insects. Particular care should be taken outside
around food and garbage, which especially attract yellow
jackets. Individuals at risk are advised to carry epinephrine,
available in preloaded syringes, for self-administration.
Epinephrine should be administered at the earliest sign of
an allergic reaction from an insect sting. Studies compar-
ing individuals who have had fatal allergic reactions with
individuals who have had serious, non-fatal reactions
suggest that the use of epinephrine may be the critical,
decisive factor in determining the outcome.7
Venom immunotherapy
Insect venom extracts for diagnosis and therapy have been
available for approximately 20 years. While some ques-
tions remain, the concepts of treatment have been well
established. Venom immunotherapy is remarkably effec-
tive, preventing subsequent allergic reactions in over 98%
of treated patients and, in many instances, providing a
permanent ‘cure’.17,18 The major remaining issues relate
to refining of the selection process for individuals requiring
VIT and refining criteria for the duration of treatment.
Patient selection (Table 1)
Potential candidates for VIT are individuals who have had
an allergic reaction from an insect sting and have a posi-
tive venom skin test or elevated levels of serum venom
specific IgE. As noted above, studies of the natural history
of insect sting allergy have shown that only approximately
60% of these individuals will have a subsequent reaction
when re-stung. The incidence of these re-sting reactions
is influenced by age and the nature of the anaphylactic
symptoms. Adults are more likely to have re-sting reac-
tions than children and the more severe the symptoms,
the more likely the reaction will re-occur. These obser-
vations influence the decision regarding patient selection
for immunotherapy.
Children with dermal (hives, angiedema) reactions
only have a very benign prognosis and do not require
immunotherapy. The incidence of re-sting reactions is
low and when the reactions do occur, they are almost
always similar in intensity.9 Individuals of any age who
have had severe allergic reactions should be advised to
receive VIT. This is particularly true of individuals who
have had loss of consciousness. Current recommenda-
tions are to administer VIT to adults who have had mild to
moderate allergic sting reactions. This decision may
require evaluation of other risk factors such as coexisting
medical problems, concomitant medication use, patient
lifestyle and risk of sting exposure.
Individuals who have had serum sickness like reactions
are also candidates for VIT.11 These individuals have ele-
vated levels of venom specific IgE and usually undetectable
or low levels of venom specific IgG. As with individuals who
have had classic serum sickness from horse serum prod-
ucts, they are now at risk for anaphylaxis if re-exposed
to venom. Venom immunotherapy has been administered
with no adverse consequences, in particular no signs of
immune complex disease.
A diagnostic sting challenge has been suggested as a
criterion for initiating venom immunotherapy.19,20 This
approach has been suggested because of the repeated
observation that only 60% of individuals thought to be at
risk for a sting reaction, because of a history of a prior
reaction and the presence of a positive skin test, do react
when re-stung. The problems with the sting challenge
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Table 1. Indications for venom immunotherapy in patients
with positive venom skin tests
Insect sting reaction Venom immunotherapy
Normal – transient pain, swelling No
Extensive local swelling No
Anaphylaxis – severe Yes





relate to its safety and reliability. Observations of both
field stings and intentional sting challenges have shown
similar results. Approximately 20% of individuals who ini-
tially tolerate a re-sting with no difficulty react following a
subsequent re-sting.10,21 More importantly, this diagnostic
sting challenge raises serious medical and ethical issues.
Life threatening reactions have occured after intentional
sting challenges in patients who did not receive VIT.20,22 It
is my opinion that patients who have a high risk of serious
anaphylaxis, such as adults who have had prior severe
reactions, should not be intentionally rechallenged and
should be given immunotherapy on the basis of their
history and skin test reactivity, recognizing that some of
these patients may not need therapy.
Venom selection
The commercial venom product brochure recommends
treatment with all venoms to which there are positive skin
tests. As a result, many individuals are treated with mul-
tiple venoms, despite the history of a single sting reaction.
The basic issue is really whether multiple venom skin test
reactions represent specific venom allergy or antigenic
cross reactivity among different venoms. Extensive studies
of venom cross reactivity may be summarized as follows:
1 There is extensive cross reactivity between the two
major North American hornet venoms, yellow hornet and
bald-faced hornet.23
2 There is extensive cross reactivity between yellow
jacket venom and hornet venom.24
3 There is limited cross reactivity between yellow
jacket and Polistes venom.25
4 There is a more complex relationship between
honeybee venom and vespid venom. There may be no
cross reaction, extensive cross reaction or reaction to a
major allergen in one venom cross reacting with a minor
allergen in the other venom.26
The practical application of these data suggests that
almost all individuals who have had allergic reactions due
to yellow jacket or hornet stings should be expected to
have positive skin test reactions to both of these venoms.
In this situation, our clinical studies have suggested that
immunotherapy with one venom, more commonly yellow
jacket, provides adequate protection.18 Approximately
50% of individuals who have had yellow jacket or hornet
sting reactions will also have positive skin test reactions to
Polistes venom. Polistes VIT is not necessary. The contrast
is also true. About half of the individuals who had Polistes
sting reactions will have a positive skin test to yellow jacket
or hornet venoms. These individuals can be adequately
treated with Polistes venom only.
Individuals who have positive tests to both yellow jacket
and honeybee venoms are more difficult to treat with single
venoms unless the history of the offending insect is clear.
The implications of these observations for therapy are
clear. If the offending insect can be identified accurately
or if there is a significant difference in degree of skin test
reactivity, knowledge of these cross reactions should lead
to single venom therapy whenever possible despite the
presence of multiple positive venom skin test reactions.
Dosing schedule
Venom immunotherapy is administered in a similar manner
to other forms of immunotherapy (Table 2). Treatment is
initiated in small doses, usually from 0.01 to 0.1 m g and
incremental doses are given until the maintenance dose is
reached, traditionally 100 m g. The selection of a starting
dose is really based on the intensity of the skin test reaction
rather than the nature of the anaphylactic symptoms.
A number of dosing regimens have been suggested. A
commonly used schedule suggests two or three injections
during the weekly build-up phase with doses doubled or
tripled at 30 min intervals. Maintenance doses can then be
reached in 6–8 weeks. Rush desensitization therapy has
also been given with multiple doses administered, often in
a hospital setting, over a period of 2–3 days to one week.
The more rapid schedules appear to be accompanied by
a more rapid increase in venom specific IgG. Reported
immunotherapy reaction rates with both rapid and slower
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Table 2. General venom immunotherapy dosing guidelines
Initial dose Administer 0.01–0.1 mg, depending on degree of skin test reaction
Incremental doses Schedules vary from ‘rush’ therapy, administering multiple venom injections over several days, to
traditional once-weekly injections
Maintenance dose Administer 50–100 m g of single venom or 300 m g of mixed vespid venom
Maintenance interval Every 4 weeks for the first year; every 6 weeks for the second year; every 8 weeks for the third year
Duration of therapy Stop when skin test becomes negative, or after 3–5 years
schedules vary, but are not significantly different. The criti-
cal issue is to reach the top maintenance dose.
Once the top maintenance dose is reached, it can be
administered every four weeks during the first year. Our
approach is to extend the maintenance interval to six
weeks after the first year and to eight weeks after the
second year.27,28 This has been done with no loss of clini-
cal effectiveness or increase in reaction rate. The top
recommended maintenance dose of a single venom is
100 m g. We have given 50 m g as a top dose with good
results. There is a mixed vespid preparation which con-
tains the two hornet venoms and yellow jacket venom
available for therapy. The top dose is 300 m g.
Venom immunotherapy reactions
Venom immunotherapy may cause reactions similar to
those induced by other types of allergenic extracts. These
reactions may pose a more difficult clinical problem
because, to insure protection, it is necessary to administer
maximum venom doses. Reduction of dosing, as done
with other forms of allergenic extracts, may not be clini-
cally effective. Fortunately, reactions to VIT are uncommon
and the majority of individuals are able to reach main-
tenance doses.
Large local reactions
Venoms are intrinsically irritating and cause pain at the
injection site. Local swelling may occur and can cause
considerable morbidity. There are several approaches to
minimize these reactions. The venom dose can be split
into two injections, thus limiting the amount of venom
delivered at one site. The addition of a small amount of
epinephrine with the venom may minimize the immediate
local swelling. If the swelling is extensive and particularly
delayed in onset, the addition of a small amount of
steroid with the venom usually effectively inhibits the large
local reaction.
Systemic reactions
Systemic reactions due to VIT are quite rare and much
less common than those induced by pollen immuno-
therapy. After a reaction, the next dose is usually reduced
by approximately 25% and subsequent doses are slowly
increased. If individuals are receiving multiple venoms, it
might be advisable to administer individual venoms on
separate days.
Generalized fatigue
Another reaction occasionally noted after injections of
other allergenic extracts such as molds and dust, but more
frequently with venom, is the occurence of generalized
fatigue and aching, sometimes associated with a large
local swelling. Successful treatment of this reaction is
usually accomplished with the administration of 650 mg
of aspirin, approximately 30 min before the injection and
every four hours thereafter for 24–48 h. If symptoms
persist, then steroids such as 40 mg of Prednisone admin-
istered daily for several days is usually helpful.29
Other reactions
There have been no identified adverse reactions caused
by long-term VIT. Injections appear to be safe during
pregnancy with no effect on the pregnancy or the fetus.30
Monitoring of venom immunotherapy
Venom immunotherapy is associated with initial increasing
titers of serum venom specific IgG, occasional increasing
and subsequent decreasing titers of serum venom specific
IgE, and an extremely high, successful clinical response. A
minority of patients will develop negative venom skin tests
while receiving immunotherapy. As noted below, this is one
criterion for stopping treatment. I do recommend repeat
venom tests approximately every two years.
Stimulation of venom specific IgG has been associated
with clinical immunity to insect stings.31 For individual
patients, however, there is no absolute titer which is
directly related to successful treatment. In my opinion, the
overall success rate of VIT and review of relative data
does not support the routine measurement of venom
specific IgG.32
Treatment failures
Venom immunotherapy is very effective, protecting
approximately 98% of treated individuals. If a re-sting
reaction does occur, it is initially advisable to determine
whether the appropriate venom is being administered.
Culprit insect identification is important and repeat
allergy tests may be necessary to verify specific venom
sensitivity. If the specific venom treatment is correct,
then the dose should be increased by 50–100%. For
example, if the maintenance dose is 100 m g, it should
be increased to 150 or 200 m g.
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Duration of therapy (Table 3)
The question of duration of treatment or when is it safe to
discontinue immunotherapy has posed a persistent issue.
Several criteria have been suggested as reliable guide-
lines. These include conversion to a negative venom skin
test, a fall in serum venom specific IgE to undetectable
levels and a finite period of treatment, three or five years,
regardless of the persistence of skin test reactivity or
serum antibody.
A recent position statement from the Insect Committee of
the American Academy of Allergy, Asthma, and Immuno-
logy has addressed this issue33 and these conclusions are
supported by three recently published studies.34–36 In my
opinion, these data strongly suggest that conversion to a
negative venom skin test is an absolute criterion for stop-
ping VIT.35–37 However, there have been several anecdotal
reports of individuals who continue to have allergic reac-
tions from insect stings apparently despite the presence of
a negative venom skin test, which suggests the need for
continued monitoring of this guideline.
Three to five years of VIT appears adequate for the
large majority of individuals who have had mild to mod-
erate anaphylactic reactions, despite the persistence of a
positive venom skin test.33–37 The re-sting reaction rate
after cessation of VIT is low, generally in the range of
5–10%. Individuals who have had severe anaphylactic
symptoms such as hypotension, laryngeal edema or loss
of consciousness have a higher risk of a repeat severe
systemic reaction if therapy is discontinued. For this
reason I currently recommend that individuals who have
had severe symptoms and retain positive venom skin
tests, receive immunotherapy indefinitely, which at this
point can be administered every eight to 12 weeks. Other
suggested factors which have been associated with the
occurence of re-sting reactions after cessation of VIT
include systemic reactions to VIT, persistence of signifi-
cant skin test reactivity and honey bee venom allergy
as compared to vespid venom allergy. These decisions
regarding cessation of therapy should include considera-
tion of other medical problems, concomitant medication,
patient lifestyle, and patient preference.
REFERENCES
1 Mauriello PM, Barde SH, Georgitis JW, Reisman RE.
Natural history of large location reactions from stinging
insects. J. Allergy Clin. Immunol. 1984; 74: 494–8.
2 McKenna WR. Killer bees: What the allergist should know.
Pediatr. Asthma Allergy Immunol. 1992; 4: 275–85.
3 Chaffee FH. The prevalence of bee sting allergy in an aller-
gic population. Acta Allergol. 1970; 25: 292–3.
4 Settipane GA, Boyd GK. Prevalence of bee sting allergy in
4,992 Boy Scouts. Acta Allergol. 1970; 25: 286–97.
5 Golden DBK. Epidemiology of allergy to insect venoms
and stings. Allergy Proc. 1989; 10: 103–7.
6 Lantner R, Reisman RE. Clinical and immunologic fea-
tures and subsequent course of patients with severe insect
sting anaphylaxis. J. Allergy Clin. Immunol. 1989; 84:
900–6.
7 Barnard JH. Studies of 400 Hymenoptera sting deaths in
the United States. J. Allergy Clin. Immunol. 1973; 52:
259–64.
8 Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio
FJ, Lichtenstein LM. A controlled trial of immunotherapy
in insect hypersensitivity. N. Engl. J. Med. 1978; 299:
157–61.
9 Valentine MD, Schuberth KC, Kagey-Sobotka A et al. The
value of immunotherapy with venom in children with allergy
to insect stings. N. Engl. J. Med. 1991; 23: 1601–3.
10 Reisman RE. Natural history of insect sting allergy:
Relationship of severity of symptoms of initial sting anaphy-
laxis to re-sting reactions. J. Allergy Clin. Immunol. 1992;
90: 335–9.
11 Reisman RE, Livingston A. Late onset reactions including
serum sickness, following insect stings. J. Allergy Clin.
Immunol. 1989; 84: 331–7.
12 Hunt KJ, Valentine MD, Sobotka AK, Lichtenstein LM.
Diagnosis of allergy to stinging insects by skin testing
with Hymenoptera venoms. Ann. Intern. Med. 1976; 85:
56–9.
13 Georgitis JW, Reisman RE. Venom skin tests in insect-
allergic and insect non-allergic populations. J. Allergy Clin.
Immunol. 1985; 76: 803–7.
STINGING INSECT ALLERGY 253
Table 3. Venom immunotherapy – when to stop
Suggested criteria for stopping venom immunotherapy
Conversion to a negative venom skin test
Persistence of positive venom skin test; 3–5 years of therapy
Factors which may influence decision to stop therapy
Severe anaphylactic symptoms, such as loss of consciousness, due to insect sting
Systemic reactions to venom immunotherapy
Unchanged venom skin test sensitivity during venom immunotherapy
Honey bee venom allergy (as compared to vespid venoms)
14 Light WC, Reisman RE, Wypych JI, Arbesman CE. Clinical
and immunological studies of beekeepers. Clin. Allergy
1975; 5: 389–95.
15 Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive
antibody in bee venom anaphylaxis. Johns Hopkins Med. J.
1978; 142: 1–7.
16 Schumacher MJ, Tveten MS, Egen NB. Rate and quantity of
delivery of venom from honeybee stings. J. Allergy Clin.
Immunol. 1994; 93: 831–5.
17 Valentine MD. Insect venom allergy: Diagnosis and treat-
ment. J. Allergy Clin. Immunol. 1984; 73: 299–304.
18 Reisman RE, Livingston A. Venom immunotherapy: 10 years
of experience with administration of single venoms and
50 m g maintenance doses. J. Allergy Clin. Immunol. 1992;
89: 1189–95.
19 van der Linden PWG, Hack CE, Poortman J et al. Insect
sting challenge in 138 patients: Relation between clinical
severity of anaphylaxis and mast cell activation. J. Allergy
Clin. Immunol. 1992; 90: 110–18.
20 Lichtenstein LM. A reappraisal of sting challenges: To whom
should we offer venom immunotherapy? J. Allergy Clin.
Immunol. 1994; 94: 137–8.
21 Franken HH, DuBois AEJ, Minkema HJ, van der Heide S, de
Monchy JGR. Lack of reproducibility of a single negative
sting challenge response in the assessment of anaphylactic
risk in patients with suspected yellow jacket hypersensitivity.
J. Allergy Clin. Immunol. 1994; 93: 431–5.
22 Smith PL, Kagey-Sobotka A, Bleecker ER et al. Physiologic
manifestations of human anaphylaxis. J. Clin. Invest. 1980;
66: 1072–80.
23 Mueller U, Elliott WB, Reisman RE et al. Comparison of the
biochemical and immunologic properties of venoms from
the four hornet species. J. Allergy Clin. Immunol. 1981;
67: 290–8.
24 Reisman RE, Mueller U, Wypych JI, Elliott WB, Arbesman
CE. Comparison of the allergenicity and antigenicity of
yellow jacket and hornet venoms. J. Allergy Clin. Immunol.
1982; 69: 268–74.
25 Reisman RE, Wypych JI, Mueller UR, Grant JA. Com-
parison of the allergenicity and antigenicity of Polistes
venom and other vespid venoms. J. Allergy Clin. Immunol.
1982; 70: 281–7.
26 Reisman RE, Mueller UR, Wypych JI, Lazell MI. Studies of
coexisting honeybee venom and vespid venom sensitivity.
J. Allergy Clin. Immunol. 1984; 73: 246–52.
27 Golden DBK, Kagey-Sobokta A, Valentine MD, Lichten-
stein LM. Prolonged maintenance interval in Hymenoptera
venom immunotherapy. J. Allergy Clin. Immunol. 1981;
67: 482–4.
28 Goldberg A, Reisman RE. Prolonged interval mainte-
nance venom immunotherapy. Ann. Allergy 1988; 61:
177–9.
29 Reisman RE. Late-onset reactions following venom immuno-
therapy and venom skin tests. Ann. Allergy 1988; 61:
383–7.
30 Schwartz HJ, Golden DBK, Lockey RF. Venom immuno-
therapy in the Hymenoptera allergic pregnant patient.
J. Allergy Clin. Immunol. 1990; 85: 709–12.
31 Golden DBK, Lawrence ID, Hamilton RH et al. Clinical cor-
relations of the venom specific IgG antibody level during
maintenance venom immunotherapy. J. Allergy Clin.
Immunol. 1992; 90: 386–93.
32 Reisman RE. Should routine measurements of serum venom
specified IgG be a standard of practice in patients receiving
venom immunotherapy? J. Allergy Clin. Immunol. 1992;
90: 282–4.
33 American Academy of Allergy, Asthma and Immunology
Position Statement. Report from the Committee on Insects.
J. Allergy Clin. Immunol. 1998; 101: 573–5.
34 Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichten-
stein LM. Discontinuing venom immunotherapy: Exten-
ded observations. J. Allergy Clin. Immunol. 1998; 101:
298–305.
35 Lerch E, Muller UR. Long-term protection after stopping
venom immunotherapy; Results of re-stings in 200 patients.
J. Allergy Clin. Immunol. 1998; 101: 606–12.
36 van Halteren HK, van der Linden PWG, Burgers JA,
Bartelink AKM. Discontinuation of yellow jacket venom
immunotherapy. Follow up of 75 patients by means of
deliberate sting challenge. J. Allergy Clin. Immunol. 1997;
100: 767–70.
37 Reisman RE. Duration of venom immunotherapy; relation-
ship to the severity of symptoms of initial sting anaphylaxis.
J. Allergy Clin. Immunol. 1993; 92: 831–6.
254 RE REISMAN
